Stock Mover of the Day: Cellectis SA (ADR)’s Stock Is Sell After Reaching All-Time Low

Stock Mover of the Day: Cellectis SA (ADR)'s Stock Is Sell After Reaching All Time Low

The stock of Cellectis SA (ADR) (NASDAQ:CLLS) reached all time low today, Nov, 7 and still has $15.32 target or 7.00% below today’s $16.47 share price. This indicates more downside for the $574.57 million company. This technical setup was reported by Barchart.com. If the $15.32 PT is reached, the company will be worth $40.22 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 46,439 shares traded hands. Cellectis SA (ADR) (NASDAQ:CLLS) has declined 41.03% since April 5, 2016 and is downtrending. It has underperformed by 42.99% the S&P500.

According to Zacks Investment Research, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.”

More important recent Cellectis SA (ADR) (NASDAQ:CLLS) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on March 21, 2015, also Marketwatch.com published article titled: “Plus the latest data from Realtor.com on 21 home markets across the US”, Schaeffersresearch.com published: “Cellectis SA (CLLS) Defies Sector Headwinds on Cancer Breakthrough” on May 06, 2016. More interesting news about Cellectis SA (ADR) (NASDAQ:CLLS) was released by: Bidnessetc.com and their article: “Pfizer Inc. Interested In Acquiring French Biotech Firm Cellectis SA (ADR …” with publication date: June 01, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment